Zimmer Biomet Holdings (0QQD) Share Forecast & Price Target
0QQD Analyst Ratings
Moderate Buy
6Buy14Hold0Sell
Based on 20 analysts giving stock ratings to Zimmer Biomet Holdings in the past 3 months
0QQD Stock 12 Month Forecast
Average Price Target
CHF 87.74▲(13.39% Upside)Based on 20 Wall Street analysts offering 12 month price targets for Zimmer Biomet Holdings in the last 3 months. The average price target is CHF 87.74 with a high forecast of CHF 103.41 and a low forecast of CHF 76.94. The average price target represents a 13.39% change from the last price of CHF 77.38.
Past 12 Months12 Month ForecastDec2025Sep2026
HighCHF 103.41
AverageCHF 87.74
LowCHF 76.94
Highest Price TargetHighestCHF 103.41Average Price TargetCHF 87.74Lowest Price TargetLowestCHF 76.94
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| David Toung | Argus Research | CHF 103.41 | buy | 33.64%Upside | Reiterated | 10/21/26 | ||
| Mike Kratky | Leerink Partners | CHF 87.69→CHF 80.25 | hold | 3.71%Upside | Assigned | 10/12/26 | ||
| Ryan Zimmerman | BTIG | ― | hold | ― | Reiterated | 10/09/26 | ||
| Christopher Pasquale | Barclays | CHF 82.73 | hold | 6.92%Upside | Initiated | 10/07/26 | ||
| Joanne Wuensch | Citi | CHF 81.90 | hold | 5.85%Upside | Reiterated | 10/05/26 | ||
| Kendall Au | RBC Capital | CHF 91.00 | buy | 17.61%Upside | Reiterated | 10/01/26 | ||
| Travis Steed | Bank of America Securities | CHF 91.00 | hold | 17.61%Upside | Reiterated | 09/25/26 | ||
| Richard Newitter | Truist Financial | CHF 87.69 | hold | 13.33%Upside | Reiterated | 09/16/26 | ||
| Robbie Marcus | J.P. Morgan | CHF 96.79 | hold | 25.09%Upside | Reiterated | 08/17/26 | ||
| Caitlin Roberts | Canaccord Genuity | CHF 68.66→CHF 82.73 | buy | 6.92%Upside | Reiterated | 08/10/26 | ||
| Larry Biegelsen | Wells Fargo | CHF 74.45→CHF 85.21 | hold | 10.12%Upside | Assigned | 08/06/26 | ||
| Vik Chopra | BMO Capital | CHF 78.59→CHF 79.42 | hold | 2.64%Upside | Reiterated | 08/06/26 | ||
| Rick Wise | Stifel Nicolaus | CHF 86.86→CHF 91.00 | buy | 17.61%Upside | Assigned | 08/06/26 | ||
| Lee Hambright | Bernstein | CHF 75.28→CHF 76.94 | hold | -0.57%Downside | Reiterated | 08/06/26 | ||
| Patrick Wood | UBS | CHF 95.14→CHF 99.27 | buy | 28.30%Upside | Reiterated | 08/06/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| David Toung | 10/21/26 | CHF 103.41 | buy | 33.64%Upside | Reiterated | Argus Research | ||
| Mike Kratky | 10/12/26 | CHF 87.69→CHF 80.25 | hold | 3.71%Upside | Assigned | Leerink Partners | ||
| Ryan Zimmerman | 10/09/26 | ― | hold | ― | Reiterated | BTIG | ||
| Christopher Pasquale | 10/07/26 | CHF 82.73 | hold | 6.92%Upside | Initiated | Barclays | ||
| Joanne Wuensch | 10/05/26 | CHF 81.90 | hold | 5.85%Upside | Reiterated | Citi | ||
| Kendall Au | 10/01/26 | CHF 91.00 | buy | 17.61%Upside | Reiterated | RBC Capital | ||
| Travis Steed | 09/25/26 | CHF 91.00 | hold | 17.61%Upside | Reiterated | Bank of America Securities | ||
| Richard Newitter | 09/16/26 | CHF 87.69 | hold | 13.33%Upside | Reiterated | Truist Financial | ||
| Robbie Marcus | 08/17/26 | CHF 96.79 | hold | 25.09%Upside | Reiterated | J.P. Morgan | ||
| Caitlin Roberts | 08/10/26 | CHF 68.66→CHF 82.73 | buy | 6.92%Upside | Reiterated | Canaccord Genuity | ||
| Larry Biegelsen | 08/06/26 | CHF 74.45→CHF 85.21 | hold | 10.12%Upside | Assigned | Wells Fargo | ||
| Vik Chopra | 08/06/26 | CHF 78.59→CHF 79.42 | hold | 2.64%Upside | Reiterated | BMO Capital | ||
| Rick Wise | 08/06/26 | CHF 86.86→CHF 91.00 | buy | 17.61%Upside | Assigned | Stifel Nicolaus | ||
| Lee Hambright | 08/06/26 | CHF 75.28→CHF 76.94 | hold | -0.57%Downside | Reiterated | Bernstein | ||
| Patrick Wood | 08/06/26 | CHF 95.14→CHF 99.27 | buy | 28.30%Upside | Reiterated | UBS |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Zimmer Biomet Holdings
3 Months
Success Rate6/11 ratings generated profit
55%
Average Return
-1.48%
Copying David Toung's trades and holding each position for 3 Months would result in 54.55% of your transactions generating a profit, with an average return of -1.48% per trade.
1 Year
Success Rate14/29 ratings generated profit
48%
Average Return
+4.74%
Copying Rick Wise's trades and holding each position for 1 Year would result in 48.28% of your transactions generating a profit, with an average return of +4.74% per trade.
2 Years
Success Rate6/13 ratings generated profit
46%
Average Return
-0.94%
Copying Vijay Kumar's trades and holding each position for 2 Years would result in 46.15% of your transactions generating a profit, with an average return of -0.94% per trade.
0QQD Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 6 | 5 | 10 | 9 | 7 |
| Hold | 17 | 10 | 22 | 22 | 22 |
| Sell | 1 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 24 | 15 | 32 | 31 | 29 |
In the current month, 0QQD has received 7 Buy Ratings, 22 Hold Ratings, and 0 Sell Ratings. 0QQD average Analyst price target in the past 3 months is 87.74.
0QQD Financial Forecast
HighCHF 1.58
ConsensusCHF 1.55
LowCHF 1.53
0QQD Earnings Forecast
Next quarter’s earnings estimate for 0QQD is CHF 1.55 with a range of CHF 1.53 to CHF 1.58. The previous quarter’s EPS was CHF 1.71. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighCHF 1.69B
ConsensusCHF 1.68B
LowCHF 1.67B
0QQD Sales Forecast
Next quarter’s sales forecast for 0QQD is CHF 1.68B with a range of CHF 1.67B to CHF 1.69B. The previous quarter’s sales results were CHF 1.79B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
0QQD Stock Forecast FAQ
What is GB:0QQD’s average 12-month price target, according to analysts?
Based on analyst ratings, Zimmer Biomet Holdings’s 12-month average price target is CHF87.74.
What is GB:0QQD’s upside potential, based on the analysts’ average price target?
Zimmer Biomet Holdings has 13.39% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Zimmer Biomet Holdings a Buy, Sell or Hold?
Zimmer Biomet Holdings has a consensus rating of Moderate Buy, which is based on 6 buy ratings, 14 hold ratings and 0 sell ratings.
What is Zimmer Biomet Holdings’s share price target?
The average share price target for Zimmer Biomet Holdings is CHF87.74. This is based on 20 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is CHF103.41, and the lowest forecast is CHF76.94. The average share price target represents a 13.39% increase from the current price of CHF77.376.
What do analysts say about Zimmer Biomet Holdings?
Zimmer Biomet Holdings’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 20 Wall Street analysts.
How can I buy shares of Zimmer Biomet Holdings?
To buy shares of GB:0QQD, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.